EYER, Luděk, Pavel SVOBODA, Jan BALVAN, Tomáš VIČAR, Martina RAUDENSKÁ, Michal ŠTEFÁNIK, Jan HAVIERNIK, Ivana HUVAROVÁ, Petra STRAKOVÁ, Ivo RUDOLF, Zdeněk HUBÁLEK, Katherine SELEY-RADTKE, Erik DE CLERCQ and Daniel RŮŽEK. Broad-Spectrum Antiviral Activity of 3'-Deoxy-3'Fluoroadenosine against Emerging Flaviviruses. Antimicrobial Agents and Chemotherapy. Washington: AMER SOC MICROBIOLOG, 2021, vol. 65, No 2, p. 1-19. ISSN 0066-4804. Available from: https://dx.doi.org/10.1128/AAC.01522-20.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Broad-Spectrum Antiviral Activity of 3'-Deoxy-3'Fluoroadenosine against Emerging Flaviviruses
Authors EYER, Luděk (203 Czech Republic, guarantor), Pavel SVOBODA (203 Czech Republic), Jan BALVAN (203 Czech Republic, belonging to the institution), Tomáš VIČAR (203 Czech Republic, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Michal ŠTEFÁNIK (203 Czech Republic), Jan HAVIERNIK (203 Czech Republic, belonging to the institution), Ivana HUVAROVÁ (203 Czech Republic), Petra STRAKOVÁ (203 Czech Republic), Ivo RUDOLF (203 Czech Republic, belonging to the institution), Zdeněk HUBÁLEK (203 Czech Republic), Katherine SELEY-RADTKE (840 United States of America), Erik DE CLERCQ (56 Belgium) and Daniel RŮŽEK (203 Czech Republic).
Edition Antimicrobial Agents and Chemotherapy, Washington, AMER SOC MICROBIOLOG, 2021, 0066-4804.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10606 Microbiology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.938
RIV identification code RIV/00216224:14110/21:00121049
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1128/AAC.01522-20
UT WoS 000609954100018
Keywords in English nucleoside analogue; 39-deoxy-39-fluoroadenosine; flavivirus; tick-borne encephalitis virus; antiviral activity; cytotoxicity; mouse model
Tags 14110515, 14110518, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/2/2022 13:40.
Abstract
Emerging flaviviruses are causative agents of severe and life-threatening diseases, against which no approved therapies are available. Among the nucleoside analogues, which represent a promising group of potentially therapeutic compounds, fluorine-substituted nucleosides are characterized by unique structural and functional properties. Despite having first been synthesized almost 5 decades ago, they still offer new therapeutic opportunities as inhibitors of essential viral or cellular enzymes active in nucleic acid replication/transcription or nucleoside/nucleotide metabolism. Here, we report evaluation of the antiflaviviral activity of 28 nucleoside analogues, each modified with a fluoro substituent at different positions of the ribose ring and/or heterocyclic nucleobase. Our antiviral screening revealed that 3'deoxy-3'-fluoroadenosine exerted a low-micromolar antiviral effect against tick-borne encephalitis virus (TBEV), Zika virus, and West Nile virus (WNV) (EC50 values from 1.1 +/- 0.1 mu M to 4.7 +/- 1.5 mu M), which was manifested in host cell lines of neural and extraneural origin. The compound did not display any measurable cytotoxicity up to concentrations of 25 mu M but had an observable cytostatic effect, resulting in suppression of cell proliferation at concentrations of > 12.5 mu M. Novel approaches based on quantitative phase imaging using holographic microscopy were developed for advanced characterization of antiviral and cytotoxic profiles of 3'-deoxy-3'-fluoroadenosine in vitro. In addition to its antiviral activity in cell cultures, 3'-deoxy-3'-fluoroadenosine was active in vivo in mouse models of TBEV and WNV infection. Our results demonstrate that fluoro-modified nucleosides represent a group of bioactive molecules with excellent potential to serve as prospective broad-spectrum antivirals in antiviral research and drug development.
PrintDisplayed: 26/4/2024 05:11